Renaissance Technologies’s Galectin Therapeutics GALT Stock Holding History

Renaissance Technologies’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$413K	Buy	+147,900	New	+$450K	﹤0.01%	2679
2022 Q3	–	Sell	-27,700	Closed	-$36K	–	4151
2022 Q2	$36K	Sell	27,700 -174,318	-86%	-$251K	﹤0.01%	4050
2022 Q1	$325K	Sell	202,018 -13,382	-6%	-$25.9K	﹤0.01%	3435
2021 Q4	$446K	Buy	215,400 +205,304	+2,034%	+$586K	﹤0.01%	3129
2021 Q3	$39K	Sell	10,096 -360,103	-97%	-$1.22M	﹤0.01%	3388
2021 Q2	$1.19M	Buy	370,199 +63,199	+21%	+$225K	﹤0.01%	2581
2021 Q1	$666K	Buy	307,000 +291,373	+1,865%	+$653K	﹤0.01%	2794
2020 Q4	$35K	Buy	+15,627	New	+$41K	﹤0.01%	3331
2020 Q2	–	Sell	-20,100	Closed	-$39K	–	3558
2020 Q1	$39K	Sell	20,100 -19,000	-49%	-$46.2K	﹤0.01%	3343
2019 Q4	$112K	Buy	+39,100	New	+$136K	﹤0.01%	3301
2019 Q3	–	Sell	-34,732	Closed	-$144K	–	3511
2019 Q2	$144K	Buy	+34,732	New	+$150K	﹤0.01%	3354
2018 Q3	–	Sell	-37,300	Closed	-$237K	–	3402
2018 Q2	$237K	Buy	+37,300	New	+$182K	﹤0.01%	3038

Other funds holding GALT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Renaissance Technologies's GALT Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Galectin Therapeutics (GALT) in Q1 2026: 147,900 shares worth $413K. The stake represents ﹤0.01% of the portfolio and ranks #2679 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in GALT as recently as Q2 2022.

Renaissance Technologies first reported a position in GALT in Q2 2018 and has held it in 12 quarters since. The position peaked at $1.19M in Q2 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

Renaissance Technologies held 147,900 shares of Galectin Therapeutics worth $413K as of Q1 2026.
Galectin Therapeutics was a new Renaissance Technologies position in Q1 2026.
Galectin Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2679 holding.
Renaissance Technologies first reported a position in Galectin Therapeutics in Q2 2018 and has held it in 12 quarters since.
Renaissance Technologies's Galectin Therapeutics position peaked at $1.19M in Q2 2021.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.